In patients with HIV/AIDS, neuropathic pain is a common neurological complication. Infection with the HIV itself may lead to neuropathic pain, and painful symptoms are enhanced when patients are treated with nucleoside reverse transcriptase inhibitors (NRTIs). The mechanisms by which NRTIs contribute to the development of neuropathic pain are not known. In the current studies, we tested the role of TNFa in antiretroviral drug-induced neuropathic pain. We administered 2 0 ,3 0 -dideoxycytidine (ddC, one of the NRTIs) systemically to induce mechanical allodynia. We found that ddC induced overexpression of both mRNA and proteins of GFAP and TNFa in the spinal dorsal horn. TNFa was colocalized with GFAP in the spinal dorsal horn and with NeuN in the DRG. Knockdown of TNFa with siRNA blocked the mechanical allodynia induced by ddC. Intrathecal administration of glial inhibitor or recombinant TNF soluble receptor, reversed mechanical allodynia induced by ddC. These results suggest that TNFa is involved in NRTIinduced neuropathic pain.
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Introduction
Highly active antiretroviral therapy (HAART) has markedly increased survival of patients with HIV/AIDS from the introduction since 1996 (Sacktor, 2002; Beck et al., 1999) . HAART contains nucleoside reverse transcriptase inhibitors (NRTIs) as an active component. NRTIs decrease plasma viral load, and can result in improvements in immune function (e.g., CD4 lymphocyte count recovery) in patients with HIV. However, drug toxicity of NRTIs limits the successful treatment in many individuals (see review; Haas et al., 2006) . Patients receiving NRTIs therapy develop a distal symmetric small fiber 'dying back' axonal neuropathy with pain (Dalakas, 2001; Dubinsky et al., 1989; Pardo et al., 2001; Reliquet et al., 2001; Simpson, 2002) . Neuropathic pain associated with the use of NRTIs is clinically quite common (Berger et al., 1993; Luciano et al., 2003) , though the mechanisms underlying this phenomenon are yet to be determined. The antiviral agent 2 0 ,3 0 -dideoxycytidine (ddC, one of the NRTIs) to patients with HIV, was approved in 1992 as an antiretroviral drug for people with HIV infection. The ddC was used particularly for patients who are intolerant of or ineligible for AZT/ddI. The ddC is still widely used in clinics in Africa, Europe and Asia. Clinical studies show that ddC increases the risk of occurrence of neuropathic pain in HIV-1 infected patients (Arenas-Pinto et al., 2008; Dalakas et al., 2001; Lopez et al., 2004; McCarthy et al., 2000) .
The cellular effects of NRTIs that could potentially contribute to the development of neuropathic pain, include cellular toxicity following the inhibition of mitochondrial DNA polymerase c (Dalakas et al., 2001; Kakuda, 2000) and upregulation of CXCR4 receptor, SDF-1 and CCL2 (Bhangoo et al., 2007; Wallace et al., 2007) . However, the detailed mechanism by which these patients with HIV/ AIDS experienced pain remains unknown. Tumor necrosis factor alpha (TNFa) is expressed on activated macrophages and lymphocytes as well as other cell types (e.g., glia in the CNS). In the chronic pain state, previous studies indicate that TNFa is increased by spinal cord injury (Peng et al., 2006) , spinal nerve ligation (Cui et al., 2008; Hao et al., 2007b) , and formalin injection into the paw in rats (Choi et al., 2008; Zhou et al., 2008) . We hypothesize that ddC may induce neuropathic pain through overexpression of TNFa in the DRG and/or spinal cord. In the present study, we found that TNFa played an important role in the neuropathic pain induced by ddC. 
Methods

Animal experiments
